X
LYEL icon

Xponance’s Lyell Immunopharma LYEL Stock Holding History

Xponance’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-563
Closed -$6.06K – 1528
2025
Q1 		$6.06K Buy
563
+13
+2% +$159 ﹤0.01% 1443
2024
Q4 		$7.04K Buy
550
+47
+9% +$932 ﹤0.01% 1442
2024
Q3 		$13.9K Hold
503
– – ﹤0.01% 1386
2024
Q2 		$14.6K Sell
503
-31
-6% -$1.48K ﹤0.01% 1312
2024
Q1 		$23.8K Buy
534
+20
+4% +$856 ﹤0.01% 1293
2023
Q4 		$19.9K Hold
514
– – ﹤0.01% 1266
2023
Q3 		$15.1K Buy
+514
New +$24.4K ﹤0.01% 1239

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Xponance's LYEL Position: Q2 2025 in Review

Xponance sold out of Lyell Immunopharma (LYEL) in Q2 2025, closing a stake of 563 shares — an estimated $6.06K sold.

Xponance first reported a position in LYEL in Q3 2023 and held it in 7 quarters. The position peaked at $23.8K in Q1 2024. 69 funds tracked by Wall St. Rank hold LYEL as of Q2 2025.

  • Xponance reported no remaining Lyell Immunopharma position as of Q2 2025 after selling out during the quarter.
  • Xponance sold 563 Lyell Immunopharma shares in Q2 2025, an estimated $6.06K.
  • Xponance first reported a position in Lyell Immunopharma in Q3 2023 and held it in 7 quarters.
  • Xponance's Lyell Immunopharma position peaked at $23.8K in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2025.

Based on Xponance's 13F filing for Q2 2025, filed 14 Aug 2025.